| Market Cap | 18.66B | P/E | 25.06 | EPS this Y | 1.80% | Ern Qtrly Grth | 31.50% |
| Income | 515.1M | Forward P/E | 19.01 | EPS next Y | 8.90% | 50D Avg Chg | -5.00% |
| Sales | 3.97B | PEG | 2.52 | EPS past 5Y | 11.38% | 200D Avg Chg | -4.00% |
| Dividend | N/A | Price/Book | 3.58 | EPS next 5Y | 7.40% | 52W High Chg | -14.00% |
| Recommedations | 2.20 | Quick Ratio | 2.90 | Shares Outstanding | 234.73M | 52W Low Chg | 27.00% |
| Insider Own | 0.75% | ROA | 6.49% | Shares Float | 232.66M | Beta | 1.02 |
| Inst Own | 99.59% | ROE | 10.57% | Shares Shorted/Prior | 4.44M/5.47M | Price | 75.67 |
| Gross Margin | 60.99% | Profit Margin | 12.98% | Avg. Volume | 1,615,501 | Target Price | 86.21 |
| Oper. Margin | 22.38% | Earnings Date | May 2 | Volume | 2,308,192 | Change | -1.23% |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
| Needham | Buy | Apr 10, 24 |
| Evercore ISI Group | In-Line | Apr 4, 24 |
| Citigroup | Buy | Apr 3, 24 |
| UBS | Neutral | Feb 2, 24 |
| Raymond James | Outperform | Feb 2, 24 |
| Needham | Buy | Feb 2, 24 |
| UBS | Neutral | Nov 16, 23 |
| Morgan Stanley | Equal-Weight | Nov 13, 23 |
| RBC Capital | Sector Perform | Nov 10, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mitchell Essex D | Div. President, GYN.. Div. President, GYN Surgical | Nov 21 | Sell | 71.852 | 7,500 | 538,890 | 12,827 | 11/24/23 |
| MACMILLAN STEPHEN P | Chairman, President.. Chairman, President and CEO | Nov 09 | Option | 26.21 | 95,422 | 2,501,011 | 2,539,247 | 11/14/22 |
| MACMILLAN STEPHEN P | Chairman, President.. Chairman, President and CEO | Nov 09 | Sell | 75.72 | 138,422 | 10,481,314 | 2,443,825 | 11/14/22 |
| Verstreken Jan | Group President, Int.. Group President, International | May 17 | Sell | 78.795 | 6,500 | 512,168 | 64,191 | 05/19/22 |
| COHN BENJAMIN JORDAN | Principal Accounting.. Principal Accounting Officer | Feb 08 | Option | 39.96 | 8,396 | 335,504 | 25,048 | 02/08/21 |
| COHN BENJAMIN JORDAN | Principal Accounting.. Principal Accounting Officer | Feb 08 | Sell | 84.31 | 8,396 | 707,867 | 16,652 | 02/08/21 |
| Griffin John M. | General Counsel General Counsel | Nov 20 | Option | 39.96 | 22,900 | 915,084 | 157,386 | 11/20/20 |
| Griffin John M. | General Counsel General Counsel | Nov 20 | Sell | 71.08 | 22,900 | 1,627,732 | 134,486 | 11/20/20 |
| Stamoulis Christiana | Director Director | Nov 06 | Option | 22.35 | 11,146 | 249,113 | 50,538 | 11/06/20 |
| Stamoulis Christiana | Director Director | Nov 06 | Sell | 74 | 11,146 | 824,804 | 39,392 | 11/06/20 |
| Oberton Karleen Marie | Chief Financial Offi.. Chief Financial Officer | Sep 23 | Option | 26.21 | 20,461 | 536,283 | 34,417 | 09/23/20 |
| Oberton Karleen Marie | Chief Financial Offi.. Chief Financial Officer | Sep 23 | Sell | 62.5 | 15,000 | 937,500 | 28,956 | 09/23/20 |